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Abstract
Aim: To describe fournovel primary epithelial tumours of the sella with papillary architecture 
and TTF-1 expression. 
Methods:Paraffin embedded tissue from the four cases and recurrence of patient 1was 
investigated with haematoxylin-eosin, special histochemical stains, immunohistochemistry with a 
broad panel of antibodies,and next generation sequencing. The ultrastructure of one tumour was 
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Results: The lesions occurred in three females aged 20, 26 and 42 years and a male aged 49years. 
They presented with signs and symptoms secondary to pituitary stalk compression. Pre-
operative neuroimaging documented mixed solid and cystic, enhancing sellar masses with 
suprasellar extension. Histologically, the tumours showed thin papillae lined by a single layer of 
cytokeratin and TTF-1 positive cuboidal and cylindrical cells with mildly atypical nucleus. Next 
generation sequencing performed in three cases did not identify any mutations. The main 
differential diagnosis included metastasis from lung or thyroid carcinoma,extra-ventricular 
choroid plexus papilloma,and sellar ependymoma. 
Conclusion: We suggest the descriptive term of primary papillary epithelial tumour of the sella 
(PPETS) for this entity and propose that it could represent the intracranial equivalent of thyroid-
like low-grade nasopharyngeal papillary adenocarcinoma. The cell of origin of PPETS remains 
undetermined although the intense and ubiquitous expression of TTF-1 may suggest a derivation 
fromthe infundibulum or ventricular recess. Our study expands the spectrum of sellar TTF-1-
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Introduction
Primary non-neuroendocrine tumours of the pituitary gland account for about 10% of sellar 
region neoplasms. Of these,about 1% compriserare lesionsincludingthe group of Thyroid 
Transcription Factor-1 (TTF-1)-expressing tumours of the posterior lobe, neural and para-
neuronal tumours, salivary gland-like tumours, ectopic choroid plexus papilloma (eCPP), 
primary sellar melanocytic neoplasms, and primary sellar atypical teratoid rhabdoid 
tumours[1,2,3]. Due to their rarity, the last four entitieshave not been included in the WHO 
Classification of Pituitary Tumours[4]. 
Thyroid Transcription Factor-1is a38kDa nuclear DNA binding protein that belongs to the NKX2 
homeodomain transcription factor family. TTF-1 has a critical role in controlling embryonic 
development and differentiation. It activates the expression of a set of genes in the thyroid gland 
and lung,and is also expressed in basal ganglia neurons, cortical interneurons, 
hypothalamicneurons, ependymal cells of the third ventricle, tanycytes and pituicytes. Deletion 
of T/EBP (TTF-1) in mice results in defects in the ventral region of the forebrain. Theoncogenic 
role of TTF-1 remains enigmatic. Current evidence indicates that gene networks regulated by 
NKX2-1/TTF-1 might be different in normal and neoplastic tissues and even among different 
tumour types[5,6,7,8]. 
We documentfour primary epithelial tumours of the sella with striking papillary architecture 
andintense TTF-1 nuclear expression. We propose the descriptive name of primary papillary 
epithelial tumour of the sella (PPETS) to define the entity and suggest PPETS could represent the 
sellar equivalent of thyroid-like low-grade nasopharyngeal papillary adenocarcinoma (TL-
LGNPPA) [9,10,11]. Given their similarities,PPETS and tumours previously documented as sellar 
eCCP may represent the same entity. PPETSexpands the spectrum of TTF-1 expressing tumours 
of the sellar region and its existence challenges the view thatTTF-1 positive tumoursof the 
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Patient 1: A 20-year-old female presented witha 3-month history of headache and secondary 
amenorrhoea for the last 5 months. On examination, she had bitemporal hemianopia. Her visual 
field defect gradually progressed and she also developed diplopia. She was otherwisewell, and 
her neurological examination was normal. Pituitary hormones were as follow: Prolactin 50.2 
ng/ml (women 4.79-23.3 ng/ml); GH 0.7 (basal <1 ng/ml); ACTH 18 (5-60 pg/ml); TSH 2.74 
(0.27-4.2 micro IU/ml); FSH 8.51 (women 3.5-12.5 mIU/ml); LH 3.65 (women 2.4-12.6 
mIU/ml).Clinical and biochemical features were consistent with normo-gonadotropic 
hypogonadism. 
A Magnetic Resonance Imaging (MRI) scan showed a solid and cystic, heterogeneously 
enhancingintra-sellar tumour measuring 45x35x25mm, encroaching on the optic chiasm and 
extending to the third ventricle. The sellar floor was intact. No extension into the cavernous 
sinuseswas noted,corresponding toKnosp grade 2 [15].A pre-operative diagnosis of pituitary 
macroadenoma was considered. A month after onset, the patient underwent a trans-nasal, trans-
sphenoidal approach withgross total excision of the tumour. Subsequently, shewas put 
onhormone replacement andremained well for the following 10 months when she returned to 
clinic complaining of visual disturbances and headache. An MRI documented tumour 
regrowth.The recurrencemeasured 37x30x25mm and similar to the primary tumour,it did not 
invade the adjacent bone or extend to the cavernous sinus. The recurrence was again removed 
trans-sphenoidally. Extensive investigations including total body MRI, thyroid ultrasound and 
PET scan returned negative results. She has beenkepton hormone replacement since 
investigations did not reveal any other lesions. The patient has been on close follow-up and she is 
well and free of disease at the last visit51 months after surgery. 
Patient 2: This 26-year-old female presented with a short history of amenorrhoea. She had her 
first menstrual cycle at the age of 13 years,but her cycles had always been irregular. For this 
reason, she had been on combined systemic oestrogen and progesteronereplacement therapyfor 
five years, which was suspended4 years before her current presentation. Her family history 
included diabetes, dyslipidaemia, glioma and breast cancer in distant relatives. More recently, 
she also developed galactorrhoea. Prolactin level was 52.45ng/dL (0min) and 50.05ng/dL 
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An MRI study of the sella documented a solid and cystic lesion measuring 18x26x18mm that 
returned a hyperintense signal on T2-weighted sequences apart from a hypointense component 
toward the sellar floor. The lesion enhanced after gadolinium administration and impinged on 
the optic chiasm and third ventricle(Figures 1a, 1b). No extension to the cavernous sinuses was 
present (Knosp grade 2). The possibility of craniopharyngioma was suggested pre-operatively. A 
CT-scan demonstrated thinning of the sellar floor and possible breach of the bone with possible 
small extension to the sphenoid sinus. No other lesions with the nasal cavities or sphenoid sinus 
were observed.On confrontation, visual field exam was normal on both sides.  Her hormonal 
status included central hypoadrenalism (peak cortisol 9.8 μg/dl, ACTH 7.8 pg/ml) and central 
hypothyroidism (fT4 5.1 pmol/l,TSH 2.7 mU/l). Prior to surgery, she was therefore commenced 
onthyroxine,hydrocortisone and vitamin D supplement.She underwent transsphenoidal 
surgerywith gross total removal of the lesion. She developed diabetes insipidus post-operatively, 
treated withdesmopressin acetate 60μg 1cp/day. Following surgery, ACTH secretion returned to 
normality and her adrenal and thyroid function recovered.Hormone replacement therapy was 
therefore suspended2 months after surgery.Given the histological diagnosis, she was extensively 
investigated with total body CT-scan and FdG PET and no other lesions were discovered. At the 
last follow-up visit a year after surgery, she had normal thyroid, adrenal and GH functions. 
Conversely, normo-gonadotropic hypogonadism persisted, requiring adequate supplementation 
therapy. Diabetes insipidus resolved. MRI showed no evidence of recurrent disease.  
Patient 3:This49-year-old male patient was identified by reviewing retrospectively the cases 
referred to the Department of Pathology and Laboratory Medicine at Mayo Clinic, Rochester, 
MN. The clinical history and tissue available for review are therefore limited.The patient 
presented to medical observation with visual symptoms. Neuroimaging documented asolid and 
cystic pituitary mass that was diagnosed as non-functioning pituitary adenoma, for which he 
underwent transsphenoidal surgery.
Given the papillary architecture, the lesion was diagnosed as possible metastasis from a thyroid 
primary. The patient underwent a totalthyroidectomy that revealed twofoci of papillary 
microcarcinoma (PMC) measuring3mm and 1.5mm respectively. No evidence of disease 
elsewherewas found including loco-regional lymph nodes with total body CT-scan and 131I-scan. 
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years after transsphenoidal surgery, he underwent a nephrectomy for a chromophobe renal cell 
carcinoma and three years later, he developed chronic renal failure.He also developed seizures, 
which are controlledmedically. At the last available follow-up, 11 years from the original 
presentation,he had no evidence of a pituitary recurrence or of any metastatic deposits from his 
PMC.
Patient 4:A 42-year-old female presented with paraesthesia in the upper limbs, more evident at 
the left site with numbnessin the territory of the third branch of trigeminal nerve. No other 
neurological defectswere found. She did not have avisual field defect on confrontation. Pituitary 
hormones levels were normal. She underwent brainMRI, which showed a sellar and suprasellar 
solid and cystic lesion measuring 20x16x28 mm with calcification (Supplementary figure1a and 
1b). The optic chiasm was compressed.No compression of the third, fourth and sixthcranial 
nerves or invasion of the cavernous sinus was present. She underwent trans-sphenoidal 
surgeryleading toa gross total removal of the lesion.Post-operatively,she developed transient 
diabetes insipidus and adrenal cortical insufficiency, initially treated with desmopressin and 
steroids but it then resolved.No other tumour was found outside the sella.
Methods
Tissuefrom the four tumours and recurrence of patient 1 were fixed in formalin andprocessed to 
paraffin embedding. Five-micron thick sections were cut from each block and stained with 
haematoxylin-eosin (H&E), Periodic Acid Schiff (PAS), PAS following diastase treatment, and 
Masson-Fontana and Gordon-Sweet’s silver impregnation for reticulin fibres. The lesions from 
patients 1, 2, and 4 were investigated with immunohistochemistry on aBenchMark ULTRA Slide 
Staining System (Roche Diagnostics, Indianapolis, IN, USA), using the following primary 
antibodies directed against: pancytokeratin (Novocastra Newcastle UK; cocktail monoclonal AE1 
and AE3; dilution 1:50), cytokeratin 7 (Dako Agilent Stockport UK, monoclonal OV-TL 12/3, 
dilution 1:50), cytokeratin 8 (Becton Dickinson San Jose CA, monoclonal CAM5.2;dilution 1:50), 
cytokeratin 20 (Dako Agilent, Ks20.8; dilution 1:50), EMA (Novocastra, monoclonal GP1.4; 
dilution 1:500), TTF-1 (Novostastra, monoclonal clone SPT24; dilution 1:50; Dako Agilent, 
8G7G3/1; dilution 1:100), CDX2 (Cell Marque, Rocklin, California, USA, monoclonal AMT28, 
dilution 1:50), -catenin (Ventana/Roche, monoclonal clone 14; dilution 1:1), chromogranin A 
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27G12; dilution 1:500), vimentin (Dako Agilent, monoclonal SRL-33; dilution 1:200), GFAP (Dako 
Agilent, monoclonal 6F2; dilution 1:1000), S-100 protein (Dako Agilent; polyclonal; 1:1000); 
NapsinA (Novocastra, monoclonal IP64; dilution 1:500), thyroglobulin (Dako Agilent, DAK-Tg6; 
dilution 1:100), HMB45 (Dako Agilent, monoclonal M0634; dilution 1:50), PAX8 (Proteintech, 
polyclonal; dilution 1:250), Transthyretin (Novocastra, polyclonal; dilution 1:100), LIN28A 
(Abcam, Cambridge UK, rabbit polyclonal, dilution 1:100), OLIG-2 (Abcam, rabbit polyclonal, 
dilution 1:200), cKIT(CD117) (Leica Biosystem, Breckland, Linford Wood, Milton Keynes, UK, 
monoclonal NCL-L-CD117, dilution 1:300),alpha-fetoprotein (Dako Agilent, rabbit polyclonal, 
dilution 1:500), OCT3/4 (Leica Buffalo Grove, USA, mouse monoclonal NCL-L-OCT3/4, dilution 
1:100), Ki-67 (Dako Agilent; monoclonal MIB-1, dilution 1:100), INI-1 (Cell Marque, monoclonal 
MRQ27; dilution 1:500), FSH (Cell Marque  Darmstadt Germany, monoclonal 83/122A8; 1:2000), 
LH (Cell Marque, monoclonal 3LH5B6Y; dilution 1:100), TSH (Cell Marque, monoclonal 5404; 
dilution 1:50), PRL (Biogenex, monoclonal BGX031A; dilution 1:50), ACTH (Dako Agilent, 
monoclonal, clone 02A3; dilution 1:1000), GH (Cell Marque, monoclonal 54/92A2; dilution1:50), 
Steroidogenic Factor 1 (Abcam Cambridge UK, monoclonal EPR19744; 1:150), PIT (Novus 
Biologicals Abingdon Oxon UK, polyclonal; dilution 1:100), TPIT (Atlas Antibodies, Stockholm 
Sweden;monoclonal CL6251; 1:300), EGFR (Dako Agilent, clone H11, code M3563; dilution 1:50), 
BRAFV600E (Ventana ,VE1 clone; pre-diluted) and CD68 (Dako Agilent, clone KP1; dilution 
1:200).
A limited immunopanel including AE1 and AE3, cytokeratin 7, cytokeratin 8, EMA, TTF-1 (clone 
SPT24), GFAP, S-100, thyroglobulinand pituitary hormones was available for the tumour from 
patient 3. The paraffin block of this patient was disposed of 10 years after surgery. No further 
immunostains or molecular analysis was possible. 
The Ki-67 labelling index was calculated as the number of positive cells out the overall number of 
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A fragment from the primary tumour of patient 1 was retrievedand reprocessed for electron 
microscopy from the paraffin block. After dewaxing in xylene and rehydration to distilled water, 
the fragments were fixed in 3% glutaraldehyde, post-fixed in 1% osmium tetroxide and 
embedded in Taab-812 epoxy resin (Merck, Darmstadt Germany). The quality of specimen was 
checked on Toluidine-blue stained semithin sections. Ultrastructure was examined with 
aJEM1400plustransmission electron microscope (Joel, Peabody MA 01960, USA)
Next Generation Sequencing
For patients 1 (recurrence) and 2, genomic DNA was isolated from the formalin-fixed and 
paraffin embedded tumour samples using the cobas® DNA Sample Preparation Kit (Roche 
Diagnostics Ltd Burgess HillUK), a generic manual specimen preparation based on nucleic acid 
binding to glass fibres. Sequence analysis was carried out following PCR enrichment using a 
QIAseq Targeted DNA custom panel (Qiagen, Germantown, MD, USA) and Illumina Next 
Generation Sequencing (Illumina, San Diego CA, USA). 
The panel targeted 37 commonly mutated oncogenes (AKT1, ALK, AR, ATRX, B2M, BRAF, 
CDKN2A, CTNNB1, DDR2, EGFR, ERBB2, FGFR3, GNA11, GNAQ, GNAS, H3F3A, H3F3B, 
HIST1H3B, HIST1H3C, HIST2H3C, HRAS, IDH1, IDH2, KIT, KRAS, MAP2K1, MET, NRAS, 
PDGFRA, PIK3CA, PTEN, RET, STK11, TERT, TP53, VHL), however the whole coding sequence of 
all 37 genes was not targeted. Mutation and variant calling by custom bioinformatics analysis 
pipeline validated to detect SNVs and small insertion/deletion mutations (<40bp) to 5% mutant 
allele frequency.Alterations were categorised following American College of Medical Genetics 
guidelines and Association for Molecular Pathology tiering.
For the tumour of patient 4, the NGS panel in use at the University Hospital of Lausanne was 
tested at the time of initial diagnosis and not repeated for this study in tumours 1 and 2. DNA 
was isolated from the formalin-fixed and paraffin embedded tumour sample and an amplicon-
based DNA library was prepared using a customized primer panel targeting hotspot regions of 
52 genes relevant to cancer (custom Ion AmpliSeq panel, Ion Torrent, Thermo Fisher Scientific, 
Waltham, MA, USA), and subsequently sequenced on an Ion S5 System (Ion Torrent, 
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in patients 1 and 2 and also the following 25 gene:ABL1, APC, ATM, CDH1, CSF1R, ERBB4, EZH2, 
FBXW7, FGFR1, FGFR2, FLT3, HNF1A, JAK2, JAK3, KDR, MLH1, MPL, NOTCH1, NPM1, PTPN11, 
RB1, SMAD4, SMARCB1, SMO, and SRC.
AR, ATRX, B2M, GNA11, H3F3A, H3F3B, HIST1H3B, HIST1H3C, HIST2H3C, hTERT were not 
investigated in patient 4.
RESULTS
The four primary tumours and the recurrence of patient 1 showed similar papillary architecture, 
although some variation between cases was observed.The papillae consisted of a single layer of 
tightly packed cylindrical or cuboidal cells lininga fibro-vascular core; pseudo-stratification of 
tumour cells was seen, particularly in cases 2, 3 and 4 (Figures 2, 4, 5a, 7b). The neoplastic cells 
had eosinophilic cytoplasm and round to ovoid, slightly hyperchromatic nucleus with dense 
chromatin and inconspicuous nucleolus. No nuclear inclusions or groves were identified (Figures 
5a and 7b). The connective tissue of the fibro-vascular cores was oedematous in some papillae 
and compact and hyalinised in others. In cases 1 and 4, the core of several papillae contained 
lymphocytic infiltrates admixed with plasma cells (Figure 2a) and foamy histiocytes (Figure 7b).A 
few multinucleated giant cells were present in cases 1 and 2 (Figures5b). Focal squamous 
metaplasia was found in case 1 (Figure 3b). No glands or evidence of intra- or extra-cellular 
mucin production, ciliated or pigmentedcells were observed. There was focal microcalcification 
in cases 2, 3 and 4. Specimens from patient 1 and 2 contained fragments of anterior hypophysis 
without pathological features of note. No neurohypophysis was present. No mitoses were 
identified. There were haemosiderin-laden macrophages and extravasation of red blood cells in 
cases 1 and 2. Necrosis was present in cases 1 and 4 (Figure 7a). There was no evidence of bone 
invasion. 
The neoplastic cells expressed CK7(Figure 3a) and showed focal expression ofcytokeratin 
AE1/AE3, cytokeratin CAM5.2,and cytoplasmic and apical expression of EMA (supplementary 
figure 2). Tumours 3 and 4 showed focal CK7 and diffuse AE1/AE3 expression. Vimentin was 
expressedfocally in cases 2(Figure 6a) and 4, whileit was negative in case 1and it was not tested in 
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showing squamous metaplasia in case 1. Expression of INI-1 was retained.Multinucleated giant 
cells (cases 1 and 2) and foamy macrophages were CD68 positive. Immunoreactions for pituitary 
hormones and transcription factors, synaptophysin, chromogranin, CK20,GFAP, S-100 protein, 
transthyretin, Napsin A, thyroglobulin, PAX8, p53, EGFR, BRAFV600E,CDX2, LIN28A, OLIG-2, 
cKIT, alpha-fetoprotein and OCT3/4were negative. Both primary and the recurrentlesions 
showed Ki-67 labelling indices lower than 1% (Figure 6b). 
Ultrastructural examination was attempted in primary tumour of patient 1. Preservation of tissue 
for EM was suboptimal following retrieval from paraffin. Nevertheless, itshowed microvilli, 
intercellular tight junctions (Supplementary figure 3) and intermediate filaments further 
confirming the epithelial origin of the lesion. There were no excess mitochondria or lysosomes, 
and there was no evidence of cilia, intracytoplasmicvacuoles or membrane bound neurosecretory 
granules.
Next generation sequencing
The recurrent tumour of patient 1 and the primary lesion of patients 2 and 4 did not show any 
relevant variants in thegenes examined. No tissue was available from patient 3 for next 
generation sequencing.
Incidence of PPETs
In order to understand the frequency of PPETS, we reviewed the diagnostic database of the 
Department of Cellular Pathology at Salford Royal Foundation Trust, the Department of 
Pathology at PIGMER in Chandigarh and the Cellular Pathology Department at Humanities in 
Milan. A total of 3,139 caseswere found between January 2008 and December 2018. The original 
slides of 21 pituitary metastases operated on in the three institutions including a lung micro 
papillary adenocarcinomawere reviewed. No diagnoses of sellerependymal or seller choroid 
plexus papilloma and no PPETS other than the lesions reported here were found indicating that 
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Discussion
We have documented fourprimary intra- and suprasellar epithelial tumours with papillary 
architecture and TTF-1 expression,for which wepropose the descriptive term of PPETS. The 
lesions occurred in threefemales and one male,all presenting with signs and symptoms of mass 
effect. Neuroimaging features of the four lesions were similar and included cystic and solid, 
enhancing component, extension to the third ventricle with chiasmatic compression but no 
involvement of the cavernous sinuses.Invasion of the sellar floorwas suggested in the pre-
operative MRI in case 2. Primary Papillary Epithelial Tumour of the Sella is extremely rare. We 
only found two examples in over 3,000 tumours operated trans-sphenoidally in our institutions 
and no mention of a similar lesion is reported in large review of over 7,000 sellar and suprasellar 
lesions recently published by Abushamat and colleagues [17], further emphasising the rarity of 
PPETS. 
The absence of pituitary hormone and pituitary lineage restricted transcription factors ruled out 
the possibility of a primary tumour of adenohypophyseal cells. Given the papillary architecture, 
and expression of cytokeratins and TTF-1, PPETSwas distinguished from a metastatic papillary 
thyroid carcinoma (PTC)or lung micropapillary carcinoma[18]. The patients were carefully 
investigated over the years. No primary tumours outside the sella were found in patients 1, 2 and 
4. The immunoprofile of their lesions including absence of thyroglobulin or napsin expression, 
and the bland light microscopic features were not in keeping with a metastatic deposit.Next 
generation sequencing did not show any mutations in BRAF, HRAS,and KRAS genesthat are 
commonly mutated in PTC [19]. Finally, the absence of CDX2 expression excluded the diagnosis 
of columnar variant of PTC [20, 21].Patient 3 underwent thyroidectomy andwas found to have 
two microscopic foci of PTC, respectivelymeasuring 1.5mm and 3mm.The original slides from his 
thyroid primary lesions were reviewed. The features were typical of PTC, including 
thyroglobulin expression and were therefore different from his sellar lesion. Papillary thyroid 
carcinomas smaller than 1.0cm are definedas PMC. They are a common disease[22,23,24]. In 
several countries, the availability of more accurate diagnostic techniques along with increased 
medical surveillance has led to a considerable increase in the detection of incidental PMC without 
a corresponding increase in mortality [25]. Low-risk PMC is an indolent diseasethat does not 
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reason, the absence of any metastatic deposits in lymph nodes in patient 3 during the 11-year 
follow-up would be unusual for PTC. Also, pituitary deposits from PTC are exceedingly 
rareaccounting for 2-3% of all pituitary metastases [29,30,31,32]. Metastases to the sellaoccurmore 
often in patients who have an established diagnosisof PTC. Notably,immunostains to confirm the 
diagnosis of metastatic PTC to the pituitary were only performed in a few cases [reviewed in ref 
33]. The question of whether a few of the documented metastatic PTC to the pituitary could have 
beenexamples of PPETS and the primary thyroid lesion an incidental finding remains open. 
Rare primary tumours with papillary architecture have previously been described in the sella 
and regarded as examples ofextra-ventricular eCPP [34,35,36,37]. Sellar eCPP and PPETS are very 
similar, and although none of the published examples of sellar eCPPweretested for TTF-1, they 
could represent the same entity.Reported sellar eCPPspresent as solid orsolid/cystic, sellar and 
suprasellar lesions without cavernous sinus extension or breach of the sellar floor. Unlike 
conventional CPPs [38,39] and similar to PPETS, sellar eCPPs show diffuse expression of 
cytokeratin 7 andfocal expression of EMA andlack of cytokeratin 20 andS-100 protein. Vimentin 
was positive in two examples[36,37].Transthyretin was only tested in one sellar eCPPs and it was 
reportedly positive [37].  In addition, the suggested origin ofsellar eCPPs from ectopic choroid 
plexus rests in the sella has never been substantiated.The exceedingly rare pigmented papillary 
epithelial neoplasm of the pituitary fossawas excludedbased onthe immunoprofile asthey contain 
melanin and express transthyretin, S100, Vimentin and HMB45 and are negative for EMA and 
panCK. TTF-1 was neither tested in the original description nor in a more recently reported case 
[40,41]. One case of primary sellar papillary adenocarcinoma was documented by Hampton and 
colleagues as part of the spectrum of primary sellar tumours that arise from ectopic salivary 
gland remnants in the pars intermedia [42]. Unlike our four cases, the lesion exhibited overtly 
aggressive features including nuclear atypia and pleomorphism, prominent nucleoli, frequent 
atypical mitosis andnecrosis.  
Sellar ependymoma enters the differential diagnosis with PPETS. Sellar ependymoma belongs to 
the group of TTF-1 positive posterior pituitary tumours.Its reported features vary from those of a 
classic ependymoma with ependymal and perivascular rosettes to lesions that consist of sheets 
and fascicles,but it is best regardedas a variant of pituicytoma [1,43,44]. In addition to TTF-1 









This article is protected by copyright. All rights reserved
than cytoplasmic, apicalEMA. Ultrastructural evidence of intra- and inter-cellular lumina 
containing microvilli and cilia and cell-to-cell junctions that are reminiscent of pituicytes with 
ependymal differentiation help confirm the diagnosis [14]. Unlike PPETS, cytokeratin is only 
focally expressed in sellar ependymoma.  
Given the unusual features of PPETS, the vicinity of sella and sphenoid sinusand the possible 
breach of sellar floor in patient 2, we considerednon-salivary and non-intestinal type low-grade 
adenocarcinoma of the sinonasal tract (SNAC) in the differential diagnosis. Histologically, low-
grade SNACs can show papillary features,but they are more often composed of back-to-back 
glands and tubules with little or no intervening stroma. Cribriform and trabecular growth are 
also described [45,46,47]. As seen in PPETS, papillae and tubules are lined by a single layer of 
uniform columnar or cuboidal cells showing minimal atypia, but they typically lack TTF-1 
expression.  Also, the distinctive expression of vimentin in the basal part of the neoplastic cells in 
ETV6 SNAC [46] was not a feature of PPETS. In contrast, the light microscopic features and 
immunoprofile of PPETS are remarkably similar toTL-LGNPPA[9,10,11,48]. Review of 
neuroimaging and intra-operative inspection confirmed the sellar floor was intact in our patients, 
and no nasal or pharyngeal lesion was present. This supported the view that the three lesions 
documented here originated from the sella despite similarity withTL-LGNPPA. TL-LGNPPA is 
extremely rare. First documented by Weniget al. in 1988 [9] as a distinct entity, TL-LGNPPA has 
been included into the WHO classification of head and neck tumours in 2005 as a malignant 
neoplasm of nasopharynx. Striking papillary architecture and aberrant TTF-1 expression that 
mimic papillary thyroid carcinoma are its distinguishing features. Examples of TL-LGNPPA 
reported so far always present as polypoid intra-nasal masses, originating from theroof of the 
nasopharynx and posterior edge of the nasal septum, and with sizes up to 4cm. No examples 
occurring in the sphenoid sinus have been documented. Adenocarcinoma is a misnomer as 
surgery is curative and prognosis is excellent [10,11,48]. No local recurrence or metastatic spread 
has been reported.
The cell of origin of PPETS remains unclear. Ubiquitous, intense nuclear expression of TTF-1 
suggests the derivation from the pituitary infundibulum, median eminence or the organum 
vasculosum of the lamina terminalis rather than the anterior gland. TTF-1 is not expressed in the 
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contain cytokeratin positive cells. The neurohypophysis, organum vasculosum of the lamina 
terminalis and median eminence belong to the circumventricular organs (CVO), a complex of 
highly vascularised, midline structures lacking the normal blood–brain barrier [50,51]. Recent 
evidence suggeststhat the entire roof of the third ventricle is a common CVO progenitor domain 
and stem cell properties of CVO have been demonstrated in an animal model [52]. These findings 
might suggest the potential of stem cells to differentiate toward an epithelial phenotype giving 
rise to PPETS. On the other hand, TTF-1 is not restricted to tumours of the infundibulum. Using 
tissue microarrays, Kristensen and colleagues [53] compared the two anti-TTF-1 clones 8G7G3/1 
and SPT24 in a wide spectrum of 155 primary CNS tumours. In addition to a minority of high-
grade gliomas, they observed weak and focal expression in central neurocytoma, one 
ependymoma and one choroid plexus papilloma. Using the clone SPT24 of anti-TTF-1antibody, 
Zamecniket al. only observed TTF-1 in two ependymomas while none of the other primary CNS 
lesion they investigated was positive [54]. More recently, Asa and colleagues observed weak TTF-
1 expression in sellar neurocytoma [55].
In conclusion, we have documented a novel primary sellar tumour with striking papillary 
architecture,cytokeratinsand TTF-1 expression.This entity expands the spectrum of TTF-1-
expressing primary tumours of the Third ventricle, infundibulum and sella. The lesion should be 
distinguished from sellar metastases from thyroid and lung, sinonasal low-grade 
adenocarcinomas and sellar ependymomas. We suggest that PPETS and sellar eCPPsmay be the 
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Legends:
Figure 1 (Patient 2): Pre- (A) and post-contrast (B) T1-weighted sagittal sequences document a 
solid and cystic lesion expanding the sella and extending to the third ventricle
Figure2 (Patient 1 – primary): Cells lying papillae often show with apical snouting (A, 
haematoxylin-eosin – x10); focal squamous metaplasia is present (B, haematoxylin-eosin – x20)
Figure 3 (Patient 1 – recurrence): Neoplastic cells express cytokeratin 7 (A, immunoperoxidase – 
x10) and show nuclear TTF-1 expression (B, immunoperoxidase – x4)
Figure 4 (Patient 2): Papillae in this tumour are less cohesive than case 1; fibro-vascular cores 
contain foamy macrophages; no lymphocytes or plasma cells are present in this area 
(Haematoxylin-eosin – x4) 
Figure5 (Patient 2): Tumour cells can at times be tightly packed and show pseudostratification 
(A, haematoxylin-eosin – x10). Multi-nucleated giant cells areseen in the stalk of papillae (B, 
haematoxylin-eosin – x20)
Figure6 (Patient 2): Several tumour cells express vimentin (A, immunoperoxidase – x10); less 
than 1% of neoplastic cells are positive for Ki-67 (B, immunoperoxidase – x4) 
Figure 7 (Patient 4): the whole mount (A) of this tumour demonstrates areas of haemorrhagic 
necrosis (asterisk) accounting for the cystic component seen in the pre-operative neuroimaging. 
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Supplementary figure 1 (Patient 4): the tumour of patient 4 shows heterogenous enhancement of 
the solid areas (A, sagittal post-contrast T1-weigthed sequence); no invasion of cavenous sinues is 
present (B, axial post-contrast T1-weigthed sequence).
Supplementary figure 2(Patient 4): neoplastic cells show cytoplasmic, apical expression of EMA 
(immunoperoxidase, x20)
Supplementary figure 3: Ultrastructural examination of tissue reprocessed from paraffin shows 
intercellular tight junction (arrow) (orginal magnification x12,000; printed magnification x59,000) 
(Patient 1, primary tumour). 
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